Avaan acquires & accelerates new drug candidates to clinical proof-of-concept in India. The Avaan Model leverages faster clinical validation & capital efficiency to accelerate drug approvals in key markets worldwide.
Management Team | Past Affiliations | Dilip Mehta, MD, PhDChairman | SVP Clinical Research Pfizer, Chairman Quintiles India, Hoechst/Aventis, Current Member of FDA's Psychopharmacology Drugs Advisory Committee | Rajnish Mishra, PhDPresident & CEO | Founder & CEO Quantros | Al Kraska, PhDMedical Director | VP Clinical Development, Pfizer | Dave Dresback, PhDSVP, Pharmaceutical Development | Sr. Director, Drug Delivery & Technology Assessment, Pfizer |
Strategic Advisory Board | Past Affiliations | Richard FulmerLicensing | VP Licensing and Development, Pfizer | David McGibney, MDClinical Development | SVP Clinical Development, Pfizer | Alex Giaquinto, PhDRegulatory | SVP Global Compliance, Schering Plough | Larry StambaughBusiness Strategy & Finance | Founder & CEO, Maxim Pharmaceuticals | Robert Zerbe, MDClinical Development | SVP Clinical Research-Parke Davis, VP-Eli Lilly. Currently, CEO of Quatrx Pharmaceuticals |
|
|
|
For further enquiries, please contact:
|
|
|
Rajnish Mishra, PhD
President & CEO
Avaan Therapeutics, Inc.
Tel. (650) 776 5102
Email: rmishra@avaan.com
|
|
|
|